• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of cancer therapeutics. It is developing an internal oncology product pipeline and lead compounds through the application of its proprietary drug discovery platform, Fragments of Active Structures (FAST). The company's pre-clinical development programs include BCR-ABL Kinase Inhibitor Program that focuses on compounds, which inhibit wild-type and Gleevec-resistant mutant forms of BCR-ABL tyrosine kinase, the enzyme that is responsible for CML; and MET Tyrosine Kinase Receptor Inhibitor program that inhibits solid tumors. In addition, it develops JAK2, a non-receptor tyrosine kinase protein; and RAS that is in the lead identification stage, which regulates cell growth. The company has collaboration and license agreements with Novartis Institutes for Biomedical Research, Inc.; Cystic Fibrosis Foundation Therapeutics, Inc.; National Institutes of Health; and Eli Lilly & Company.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2008-08-20 | 0 | |
|
No longer subject to file | 2008-08-20 | 0 | |
|
GREY MICHAEL G PRESIDENT & CEO |
|
No longer subject to file | 2008-08-20 | 0 |
|
No longer subject to file | 2008-08-20 | 0 | |
|
No longer subject to file | 2008-08-20 | 0 | |
|
No longer subject to file | 2008-08-20 | 0 | |
|
No longer subject to file | 2008-08-20 | 0 | |
|
BURLEY STEPHEN CSO & SVP, RESEARCH |
|
No longer subject to file | 2008-08-20 | 0 |
|
NORTH ANNETTE GENERAL COUNSEL |
|
No longer subject to file | 2008-08-20 | 0 |
|
MYERS W TODD CFO |
|
No longer subject to file | 2008-08-20 | 0 |
|
REICH SIEGFRIED VP, DRUG DISCOVERY |
|
No longer subject to file | 2008-08-20 | 0 |
|
RUGG TERENCE ANTHONY CMO & VP, DRUG DEVELOPMENT |
|
No longer subject to file | 2008-08-20 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
